Core Viewpoint - Cracker Barrel Old Country Store reported a narrower-than-expected loss in Q1 fiscal 2026, but revenues fell short of expectations, indicating challenges in the current macro and industry environment [3][5][4]. Financial Performance - The company reported an adjusted loss per share of 74 cents, better than the Zacks Consensus Estimate of a loss of 78 cents, while the previous year showed an adjusted EPS of 45 cents [5]. - Quarterly revenues were $797.2 million, missing the consensus estimate of $801 million, and reflecting a 5.7% decrease year over year [5]. - Comparable-store restaurant sales decreased by 4.7% year over year, and comparable-store retail sales fell by 8.5% year over year [6]. Operational Highlights - The cost of goods sold (excluding depreciation and rent) was $248.4 million, down 4% year over year, but as a percentage of total revenues, it increased by 60 basis points to 31.2% [7]. - General and administrative expenses totaled $48 million, down 20% year over year [7]. - The adjusted net loss for the quarter was $16.4 million, compared to an adjusted net income of $10.2 million in the same quarter last year [8]. Balance Sheet - As of October 31, 2025, cash and cash equivalents were $8.9 million, down from $11.5 million a year earlier [9]. - Inventory reached $209.1 million, up 3.6% year over year [9]. - Long-term debt was $400.9 million, reduced from $527 million a year prior [9]. Fiscal Guidance - For fiscal 2025, the company revised its revenue guidance to a range of $3.2-$3.3 billion, down from $3.35-$3.45 billion [11]. - Adjusted EBITDA is now expected to be between $70 million and $110 million, a decrease from the previous estimate of $150 million to $190 million [11]. - Capital expenditures are projected to be between $110-$125 million, down from an earlier estimate of $135 million to $150 million [12]. Market Sentiment - Estimates for the stock have trended downward, with a significant shift of -113.98% in consensus estimates over the past month [13]. - Cracker Barrel currently holds a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [15].

Core Viewpoint - Deere's recent earnings report showed a mixed performance, with earnings per share missing estimates and a decline in net income, while net sales increased year over year, indicating potential challenges ahead for the company [2][11]. Financial Performance - Fourth-quarter fiscal 2025 earnings were $3.93 per share, missing the Zacks Consensus Estimate of $3.96, and decreased 14% from the prior year [2]. - Net sales of equipment operations reached $10.6 billion, up 14% year over year, surpassing the Zacks Consensus Estimate of $9.99 billion [3]. - Total net sales, including financial services, were $12.4 billion, an 11% increase year over year [3]. - The cost of sales rose 21% year over year to $7.94 billion, leading to a total gross profit decrease of 2.7% to $4.45 billion [4]. Segment Performance - Production & Precision Agriculture segment sales increased 10% year over year to $4.74 billion, but operating profit decreased 8% to $604 million due to higher production costs [5]. - Small Agriculture & Turf sales rose 7% to $2.46 billion, but operating profit plummeted 89% to $25 million, impacted by higher warranty expenses and tariffs [6]. - Construction & Forestry sales were $3.38 billion, up 27% year over year, with operating profit increasing 6% to $237 million [7]. - Financial Services division revenues were $1.55 billion, up 2% year over year, with net income rising to $293 million from $173 million in the prior year [8]. Cash and Debt Position - Cash and cash equivalents at the end of fiscal 2025 were $8.28 billion, up from $7.32 billion at the end of fiscal 2024 [9]. - Cash flow from operating activities was $7.5 billion in fiscal 2025, down from $9.23 billion in the prior fiscal year [9]. - Long-term borrowing increased to $43.5 billion from $43.23 billion at the end of fiscal 2024 [9]. Fiscal Guidance - For fiscal 2026, Deere expects net income between $4.00 billion and $4.75 billion, with varying projections for different segments [12]. - Production & Precision Agriculture sales are expected to decrease by 5-10%, while Small Agriculture & Turf sales are projected to rise by 10% [12]. Estimate Trends - Since the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting down by 27.39% [13]. VGM Scores - Deere has a Growth Score of B but lags in Momentum with an F, resulting in an aggregate VGM Score of C [14]. Outlook - The overall trend in estimates has been downward, leading to a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [15].

Core Viewpoint - Unum Group's recent earnings report showed a mixed performance with a decline in operating net income and rising expenses, leading to concerns about future performance as shares have underperformed the S&P 500 [1][2]. Financial Performance - Unum Group reported Q3 2025 operating net income of $2.09 per share, missing the Zacks Consensus Estimate by 2.7% and reflecting a 1.8% year-over-year decrease [2]. - Total operating revenues reached $3.4 billion, a 5% increase year-over-year, driven by higher premium income and other income, beating the Zacks Consensus Estimate by 2.5% [3]. - Premium income increased by 2.2% year-over-year to $2.7 billion, aligning with estimates [3]. Expense Analysis - Total benefits and expenses surged by 38.3% year-over-year to $3.3 billion, primarily due to higher policy benefits and other expenses, exceeding the estimate of $2.8 billion [3]. Segment Performance - Unum U.S. reported premium income of $1.7 billion, up 1.9% year-over-year, but adjusted operating income fell by 7.8% to $334.9 million, missing estimates [4]. - Unum International's premium income rose 14% year-over-year to $281.1 million, with adjusted operating income down 3.7% [5]. - The Unum U.K. line saw premium income increase by 7.6% to £171 million, but adjusted operating income decreased by 10.8% [6]. Benefit Ratio and Sales - The benefit ratio, excluding reserve assumption updates, deteriorated by 430 basis points to 73.8%, mainly due to unfavorable experiences in group long-term disability [7]. - Sales in the Unum U.K. increased by 27.3% to £29.4 million, while Colonial Life's premium income rose by 3.3% to $456.5 million [8][9]. Capital Management - As of September 30, 2025, Unum Group's risk-based capital ratio was approximately 455%, with holding company liquidity at $2 billion and book value per share growing by 8.7% year-over-year to $64.56 [13]. Market Outlook - Following the earnings release, there has been a downward trend in estimates for Unum, indicating a potential shift in market sentiment [14][16]. - Unum currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [16].

Core Viewpoint - Xenon Pharmaceuticals reported a narrower loss than expected for Q3 2025, with shares increasing by approximately 9.7% since the last earnings report, outperforming the S&P 500 [1][3]. Financial Performance - The company reported a loss of $1.15 per share for Q3 2025, which was better than the Zacks Consensus Estimate of a loss of $1.16, compared to a loss of $0.81 per share in the same quarter last year [3]. - Xenon did not generate any revenues in the reported quarter, similar to the year-ago quarter, as it lacks a marketed product and only recognizes collaboration revenues from its partnership with Neurocrine Biosciences [4]. - Research and development (R&D) expenses rose by 35% year-over-year to $77.1 million, driven by costs related to late-stage studies in epilepsy and major depressive disorder (MDD), as well as increased personnel expenses [5]. - General and administrative expenses increased by 16% year-over-year to $19.3 million, primarily due to higher professional and consulting fees [6]. - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $555.3 million, down from $624.8 million as of June 30, 2025, which is expected to fund operations through 2027 [7]. Market Sentiment and Estimates - Estimates for Xenon Pharmaceuticals have trended upward over the past month, indicating a positive outlook despite the current Zacks Rank of 3 (Hold) [8][10]. - The company has a poor Growth Score of F and a Momentum Score of C, with an overall VGM Score of F, placing it in the bottom 20% for value investors [9]. Industry Comparison - Xenon Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, where BioMarin Pharmaceutical (BMRN) has seen a 2.6% gain over the past month, reporting revenues of $776.13 million for the last quarter, a year-over-year increase of 4.1% [11][12].

Core Viewpoint - American Electric Power (AEP) reported mixed results in its Q3 2025 earnings, with revenues increasing but operating earnings per share (EPS) missing estimates, leading to questions about future performance [2][3][6]. Financial Performance - AEP's Q3 2025 operating EPS was $1.80, missing the Zacks Consensus Estimate of $1.81 by 0.6%, and declined 2.7% from $1.85 in the same quarter last year [2]. - Total revenues for AEP reached $6.01 billion, a 10.9% increase from $5.42 billion in the year-ago quarter, and exceeded the Zacks Consensus Estimate of $5.65 billion by 6.5% [3]. Segmental Performance - Vertically Integrated Utility Operations reported operating earnings of $573.5 million, slightly up from $572.4 million year-over-year [4]. - Transmission & Distribution Utilities saw operating earnings rise to $259.1 million from $245.2 million in the previous year [4]. - AEP Transmission Holdco's operating earnings decreased to $199.9 million from $214.7 million year-over-year [4]. - Generation and Marketing segment's operating earnings fell to $48.4 million from $99.2 million in the prior year [5]. - The "All Other" segment reported an operating loss of $118 million, which was an improvement from a loss of $146.1 million in the year-ago quarter [5]. Guidance and Estimates - AEP reaffirmed its 2025 operating earnings guidance, expecting to generate earnings in the range of $5.75-$5.95 per share, with the Zacks Consensus Estimate at $5.90 per share [6]. - Following the earnings release, there has been an upward trend in estimates for AEP [7]. Stock Performance and Outlook - AEP has an average Growth Score of C and a Momentum Score of A, with a value grade of C, placing it in the middle 20% for value investors [8]. - The stock has a Zacks Rank 3 (Hold), indicating an expectation of an in-line return in the coming months [9]. Industry Comparison - AEP is part of the Zacks Utility - Electric Power industry, where PG&E (PCG) has also shown a 0.7% gain over the past month, reporting revenues of $6.25 billion, a year-over-year increase of 5.2% [10]. - PG&E's EPS for the last quarter was $0.50, compared to $0.37 a year ago, and it is expected to post earnings of $0.39 per share for the current quarter, reflecting a 25.8% year-over-year change [11].

Core Insights - Leggett & Platt's Q3 2025 earnings report showed a sales decline of 6% year over year to $1.04 billion, although it exceeded the Zacks Consensus Estimate by 1.2% [2] - Adjusted EPS of 29 cents missed estimates by 3.3% and fell 9% year over year, primarily due to volume declines, despite some support from metal margin expansion [3] - The company reaffirmed its 2025 guidance, projecting sales between $4 billion and $4.1 billion, reflecting a year-over-year decline of 6-9% [8] Financial Performance - Sales in the Bedding Products segment fell 10%, with a 13% volume drop, but adjusted EBIT margin improved by 220 basis points to 6.6% due to metal margin expansion [4] - Specialized Products saw a 7% sales decline, with organic sales down 2%, while the adjusted EBIT margin slightly increased to 9.7% [4] - Gross profit was $194 million, down 3% year over year, with gross margin remaining flat; adjusted EBIT was $73 million, down 4% year over year, but adjusted EBIT margin rose by 10 basis points to 7.0% [6] Balance Sheet & Cash Flow - At the end of Q3, the company had $461 million in cash and $974 million in total liquidity, with long-term debt at $1.5 billion, down $296 million sequentially [7] - Operating cash flow improved to $126 million, up 32% year over year, driven by better working capital management [7] Market Position & Outlook - Leggett & Platt has a subpar Growth Score of D and a Momentum Score of F, but a strong Value Score of A, placing it in the top quintile for value investors [9] - The company holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return from the stock in the coming months [10]

Core Insights - Vail Resorts reported a wider-than-expected net loss for Q4 fiscal 2025, with revenues missing estimates despite a year-over-year increase [2][3] - The company experienced a decline in skier visits, yet managed to maintain a stable EBITDA margin for the full year [5][9] - There has been a downward trend in estimates for the company's performance, leading to a Zacks Rank of 5 (Strong Sell) [12][13] Financial Performance - Q4 fiscal 2025 revenues were $271.3 million, up 2.2% from $265.3 million year-over-year, but below the Zacks Consensus Estimate of $272 million [2] - The net loss attributable to shareholders was $185.5 million, or $5.08 per share, compared to a loss of $176.6 million, or $4.70 per share, in the previous year [3] - Full-year fiscal 2025 revenues reached $2.96 billion, a 2.7% increase year-over-year, with net income rising to $280 million ($7.53 per share) from $231.1 million ($6.09 per share) in fiscal 2024 [3] Margins and Profitability - Resort Reported EBITDA for Q4 was a loss of $123.6 million, compared to a loss of $114.6 million in the prior-year period, influenced by higher costs related to CEO transition and resource efficiency [4] - The full-year Resort Reported EBITDA margin was 28.5%, showing modest expansion despite a 3% decline in skier visits [5] Segment Performance - The Mountain segment net revenues increased by 2.9% year-over-year to $180.9 million in Q4, driven by dining and ski school [6] - Lodging segment net revenues were $90.3 million, up 0.9%, with Lodging Reported EBITDA growing 48% to $4.1 million [6] Balance Sheet and Capital Management - As of July 31, 2025, Vail Resorts had $440 million in cash and total liquidity of approximately $1.4 billion, with net debt at $2.75 billion [7] - The company repurchased 1.29 million shares for $200 million in Q4, totaling $270 million for the full year, representing 4.5% of outstanding shares [8] Guidance and Outlook - For fiscal 2026, Vail Resorts anticipates net income between $201 million and $276 million, with Resort Reported EBITDA projected at $842 million to $898 million, indicating a margin of roughly 28.8% [9] - The guidance reflects expected efficiency savings and normalized weather conditions, but is tempered by lower pass unit sales and cost inflation [9]

Company Overview - Allogene Therapeutics reported a narrower than expected loss of 23 cents per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of 28 cents and a loss of 35 cents per share in the same period last year [2] - The company did not report any sales during the quarter, as it lacks a marketed product, while it recorded collaboration revenues of $0.02 million in the year-ago period [2] Financial Performance - Research and development (R&D) expenses totaled $40.2 million, down 20.2% from the previous year [3] - General and administrative expenses decreased by 11.2% year over year to $14.3 million [3] - As of June 30, 2025, Allogene had $302.6 million in cash, cash equivalents, and investments, down from $335.5 million as of March 31, 2025 [3] Future Guidance - The company expects operating expenses for 2025 to be around $230 million and cash burn to be approximately $150 million, indicating that its cash runway will fund operations into the second half of 2027 [4] Market Sentiment - Since the earnings release, there has been an upward trend in estimates revision for Allogene Therapeutics [5] - The stock has a Zacks Rank 2 (Buy), indicating expectations for above-average returns in the coming months [7] Industry Comparison - Allogene Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Beam Therapeutics Inc. has gained 22.2% over the past month [8] - Beam Therapeutics reported revenues of $8.47 million for the last quarter, reflecting a year-over-year decline of 28% [9]

Core Viewpoint - Editas Medicine reported a wider-than-expected loss in Q2 2025, with shares declining approximately 16.9% since the last earnings report, underperforming the S&P 500 [1][2]. Financial Performance - Editas reported a loss of 63 cents per share in Q2 2025, which was worse than the Zacks Consensus Estimate of a loss of 41 cents, compared to a loss of 82 cents per share in the same quarter last year [2]. - Collaboration and other R&D revenues were $3.6 million in Q2 2025, significantly up from the previous year's figure and exceeding the Zacks Consensus Estimate of $1 million, primarily due to revenue recognition from achieved deliverables [3]. - R&D expenses decreased by 70% to $16.2 million compared to $54.2 million in the prior year, attributed to lower clinical and manufacturing costs following the abandonment of the reni-cel program [4]. - General and administrative expenses were $12.9 million, down 29% year-over-year due to reduced employee-related expenses from a decreased headcount [5]. - Restructuring and impairment charges amounted to $26.1 million in Q2 2025 due to the discontinuation of the reni-cel program, with no such charges recorded in the previous year [5]. - As of June 30, 2025, Editas had cash, cash equivalents, and investments totaling $178.5 million, down from $221 million as of March 31, 2025, with expectations to fund operations into Q2 2027 [6]. Market Sentiment - Estimates for Editas have trended upward over the past month, indicating a potentially positive outlook [7]. - Editas holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [9]. Industry Comparison - Editas is part of the Zacks Medical - Biomedical and Genetics industry, where GSK has gained 3.5% over the past month, reporting revenues of $10.67 billion for the last quarter, reflecting a year-over-year increase of 7.2% [11].

Core Insights - Kraft Heinz reported second-quarter 2025 results with adjusted earnings of 69 cents per share, surpassing the Zacks Consensus Estimate of 64 cents, but reflecting an 11.5% year-over-year decline [3] - The company generated net sales of $6,352 million, down 1.9% year over year, yet exceeding the Zacks Consensus Estimate of $6,286 million [4] - Organic sales decreased by 2% year over year, with a projected decline of 3.2% [4][12] Financial Performance - Adjusted gross profit was $2.17 billion, a decrease of 5.6% from the previous year, with an adjusted gross margin contraction of 140 basis points to 34.1% [6] - Adjusted operating income fell 7.5% year over year to $1.3 billion, primarily due to higher commodity cost inflation [7] - Cash and cash equivalents at the end of the quarter were $1.57 billion, with long-term debt of $19.3 billion and total shareholders' equity of $41.4 billion [10] Segment Performance - North America: Net sales of $4.76 billion declined 3.3% year over year, with organic sales down 3.2% [8] - International Developed Markets: Net sales of $897 million increased by 1.3% year over year, but organic sales declined by 2.2% [9] - Emerging Markets: Net sales of $698 million rose by 4.2% year over year, with organic sales growing by 7.6% [9] Future Outlook - For 2025, Kraft Heinz expects organic net sales to decline between 1.5% and 3.5% year over year, with management anticipating sequential improvement in organic sales [12] - The company projects adjusted earnings per share in the range of $2.51 to $2.67 [12] - Recent estimates have shown a downward trend, with a consensus estimate shift of -8.25% [13]